Premas Biotech
Gurgaon, India· Est.
Premas Biotech fast‑tracks biologics and vaccine development with patented platforms and end‑to‑end services.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Premas Biotech fast‑tracks biologics and vaccine development with patented platforms and end‑to‑end services.
OncologyImmunologyInfectious DiseasesMetabolic
Technology Platform
Premas’ core platforms include AXTEX‑4D 3D cell culture for rapid screening, D‑CRYPT high‑yield expression of difficult proteins, and C‑QWENCE a human antibody library with extensive CDR diversity.
Opportunities
Premas can leverage its platforms to meet growing demand for rapid biologics and oral vaccine development, especially in emerging markets and for pandemic preparedness.
Risk Factors
Reliance on a limited number of large partners and the need to demonstrate successful IND filings for its own candidates pose commercial and regulatory risks.
Competitive Landscape
Competitors include traditional CDMOs and specialized biologics platforms such as Lonza and WuXi, but Premas differentiates itself through integrated 3D culture, high‑yield expression, and a unique oral delivery collaboration.